A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs RG 7625 (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Sponsors Roche
- 26 Jul 2017 Status changed from active, no longer recruiting to completed.
- 30 May 2017 Planned End Date changed from 1 Jun 2017 to 7 Dec 2017.
- 30 May 2017 Planned primary completion date changed from 1 Jun 2017 to 7 Dec 2017.